- Kamada Ltd. (NASDAQ:KMDA) and collaboration partner Kedrion S.p.A. announce the filing of a Biologics License Application (BLA) in the U.S. seeking approval of Kamada's post-exposure rabies treatment human anti-rabies immune globulin (IgG). A decision is expected in mid-2017. If all goes well, the commercial launch by Kedrion will commence soon thereafter. The U.S. market is valued at over $100M. About 40K post-exposure prophylaxis treatments are administered here each year.
- Kamada has been marketing the product ex-U.S. since 2003 under the brand name KamRAB. It has sold over 1M vials to date.